Renaissance Technologies LLC increased its stake in shares of VIVUS, Inc. (NASDAQ:VVUS) by 41.2% during the first quarter, according to its most recent filing with the SEC. The fund owned 6,182,454 shares of the biopharmaceutical company’s stock after buying an additional 1,805,100 shares during the period. Renaissance Technologies LLC owned approximately 5.86% of VIVUS worth $6,924,000 at the end of the most recent reporting period.
A number of other hedge funds also recently made changes to their positions in VVUS. Oxford Asset Management boosted its stake in shares of VIVUS by 76.6% in the first quarter. Oxford Asset Management now owns 587,535 shares of the biopharmaceutical company’s stock valued at $658,000 after buying an additional 254,912 shares during the last quarter. Nine Chapters Capital Management LLC bought a new stake in shares of VIVUS during the first quarter valued at approximately $113,000. Bank of New York Mellon Corp boosted its stake in shares of VIVUS by 3.6% in the first quarter. Bank of New York Mellon Corp now owns 106,842 shares of the biopharmaceutical company’s stock valued at $120,000 after buying an additional 3,694 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its stake in shares of VIVUS by 164.7% in the first quarter. Acadian Asset Management LLC now owns 1,075,430 shares of the biopharmaceutical company’s stock valued at $1,205,000 after buying an additional 669,165 shares during the last quarter. Institutional investors and hedge funds own 35.47% of the company’s stock.
VIVUS, Inc. (NASDAQ VVUS) opened at 1.01 on Wednesday. The company has a market capitalization of $106.74 million, a PE ratio of 3.06 and a beta of 0.86. The firm’s 50 day moving average price is $1.20 and its 200-day moving average price is $1.12. VIVUS, Inc. has a 12-month low of $0.99 and a 12-month high of $1.47.
Separately, Zacks Investment Research upgraded VIVUS from a “hold” rating to a “buy” rating and set a $1.50 target price on the stock in a report on Monday, July 17th.
VIVUS Company Profile
VIVUS, Inc is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED).
Receive News & Ratings for VIVUS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
